Tinostamustine (EDO-S101)


A new phase 1/2 trial is recruiting patients with soft tissue sarcoma (including synovial sarcoma) in California and Arizona:


EDO-S101 is a mix of bendamustine and HDAC inhibitor vorinostat:

A phase 2 study of bendamustine in patients with refractory soft tissue sarcoma from Germany gave the following results in 2007: